10X Genomics Hits New 52-Week High of $38.67, Up 72.86%

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 38.67 on June 30, 2026. This achievement marks a remarkable increase from its 52-week low of USD 11.16, showcasing a substantial growth trajectory over the past year. The company's performance over the last year has been impressive, with a gain of 72.86%, significantly outpacing the S&P 500's performance of 20.86%. Despite being a loss-making entity, 10X Genomics has maintained a market capitalization of USD 2,489 million, reflecting its position within the small-cap segment of the market. Key financial metrics indicate a price-to-book ratio of 3.13, while the company currently does not offer a dividend yield. The debt-to-equity ratio stands at -0.64, and the return on equity is reported at -10.80%. These figures provide insight into the company's financial health and market standing as it continues to navigate the competitive landscape of the biotechnology industry.